application): With the dramatic expansion and increased methodologic sophistication in Alzheimer's disease (AD) research, demands on the clinical core for clearly defined samples of persons with AD and age-matched controls have become more complex. A sample of subjects appropriate for one type of investigation (such as a clinical treatment outcome trial) is often not appropriate for other types of studies (for example, a case-control epidemiologic study or genetic linkage analysis). Still, other types of samples are needed for training clinicians to manage the multiple clinical problems expressed during the course of AD. To meet these multiple demands, the clinical core has developed and will continue to provide multiple samples of AD patients and normal healthy control subjects suitable for supporting the subject recruitment needs of a broad range of research and clinical training in AD. The clinical core will continue to include probable AD and nondemented older controls selected for maximum appropriateness for participation in clinical studies. In addition, subjects with non-AD neurodegenerative demanding disorders and mild cognitive impairment will be recruited and followed in the clinical core. The genetics sample includes patients with familial AD and related familial dementias who are followed for participation in linkage analysis and other genetic studies. Clinical core personnel support and interact with population-based cohorts of AD and normal control subjects appropriate for epidemiologic studies and which provide additional sources for accession of postmortem brain tissue. Through all these subject populations, subjects are provided to meet the research needs of ADRC investigators, other appropriate investigators in the broader University of Washington research community, and investigators at other institutions.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005136-19
Application #
6593356
Study Section
Project Start
2002-06-01
Project End
2003-04-30
Budget Start
Budget End
Support Year
19
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Tulloch, Jessica; Leong, Lesley; Chen, Sunny et al. (2018) APOE DNA methylation is altered in Lewy body dementia. Alzheimers Dement 14:889-894
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Kunji, Khalid; Ullah, Ehsan; Nato Jr, Alejandro Q et al. (2018) GIGI-Quick: a fast approach to impute missing genotypes in genome-wide association family data. Bioinformatics 34:1591-1593
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Kaur, Antarpreet; Edland, Steven D; Peavy, Guerry M (2018) The MoCA-Memory Index Score: An Efficient Alternative to Paragraph Recall for the Detection of Amnestic Mild Cognitive Impairment. Alzheimer Dis Assoc Disord 32:120-124
Taylor, Laura M; McMillan, Pamela J; Liachko, Nicole F et al. (2018) Pathological phosphorylation of tau and TDP-43 by TTBK1 and TTBK2 drives neurodegeneration. Mol Neurodegener 13:7

Showing the most recent 10 out of 753 publications